Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B

Inspiration releases an important update about their clinical trial program for IB1001, an intravenous recombinant factor IX (rFIX) product that is being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. Click here for the official IBI press release.

Read more news.